X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
VENUS REMEDIES Fact Sheet, VENUS REMEDIES Financial Results - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES Fact Sheet   (VSRM)

Here is the latest financial fact sheet of VENUS REMEDIES. For more details, see the VENUS REMEDIES quarterly results and VENUS REMEDIES share price and chart. For a sector overview, read our pharmaceuticals sector report.

VENUS REMEDIES Price History

Price Rs 59.6
Mkt Cap Rs m 682
Vol '000 8.1
P/E X -532.7
P/CF X 1.4
EPS (TTM) Rs -0.1
% ch % -0.3
No. of shares m 11.44
% ch week % -0.4
% ch 1-mth % -16.6
% ch 12-mth % -38.7
52 week H/L Rs 125.9/56.1
(As on May 25, 2018 (Close))
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

VENUS REMEDIES Financials

No. of Mths
Year Ending
12
Mar-13
*
12
Mar-14
*
12
Mar-15
*
12
Mar-16
*
12
Mar-17
*
5-Yr Chart
Click to enlarge
VENUS REMEDIES EQUITY SHARE DATA
High Rs328358330218143 
Low Rs1581401038265 
Sales per share (Unadj.) Rs444.6473.4405.6365.6324.2 
Earnings per share (Unadj.) Rs54.456.24.51.56.4 
Diluted earnings per shareRs50.156.24.51.56.9 
Cash flow per share (Unadj.) Rs85.891.444.737.940.6 
Dividends per share (Unadj.) Rs3.000000 
Adj. dividends per shareRs2.760.000.000.000.00 
Dividend yield (eoy) %1.20000 
Book value per share (Unadj.) Rs359.7403.5399.2382.5366.0 
Adj. book value per shareRs331.4403.5399.2382.5394.8 
Shares outstanding (eoy) m10.5411.4411.4411.4412.34 
Bonus/Rights/Conversions  WCWC--- 
Price / Sales ratio x0.50.50.50.40.3 
Avg P/E ratio x4.54.447.9101.016.2 
P/CF ratio (eoy) x2.82.74.84.02.6 
Price / Book Value ratio x0.70.60.50.40.3 
Dividend payout %5.50000 
Avg Mkt Cap Rs m2,5602,8492,4711,7171,282 
No. of employees `000NANANA1.00.9 
Total wages/salary Rs m273305324250251 
Avg. sales/employee Rs ThNMNMNM4,100.74,430.1 
Avg. wages/employee Rs ThNMNMNM245.3278.0 
Avg. net profit/employee Rs ThNMNMNM16.787.6 
VENUS REMEDIES INCOME DATA
Net Sales Rs m4,6865,4164,6404,1834,000 
Other income Rs m4572023 
Total revenues Rs m4,6915,4204,6474,2034,023 
Gross profit Rs m1,2011,382892812785 
Depreciation Rs m331402460417422 
Interest Rs m246294412380344 
Profit before tax Rs m628691273542 
Minority Interest Rs m00000 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m00000 
Tax Rs m5548-2518-37 
Profit after tax Rs m573643521779 
Gross profit margin %25.625.519.219.419.6 
Effective tax rate %8.86.9-94.851.6-87.9 
Net profit margin %12.211.91.10.42.0 
VENUS REMEDIES BALANCE SHEET DATA
Current assets Rs m2,2562,7212,6752,7712,606 
Current liabilities Rs m1,9132,1101,9651,9311,980 
Net working cap to sales %7.311.315.320.115.6 
Current ratio x1.21.31.41.41.3 
Inventory Days Days10096112125128 
Debtors Days Days3744505443 
Net fixed assets Rs m4,0565,0735,2195,3285,353 
Share capital Rs m105114114114123 
"Free" reserves Rs m2,6064,4504,4454,2624,393 
Net worth Rs m3,7914,6164,5674,3764,516 
Long term debt Rs m1,2911,4001,6861,9111,618 
Total assets Rs m7,1768,3448,4118,4288,291 
Interest coverage x3.63.31.11.11.1 
Debt to equity ratio x0.30.30.40.40.4 
Sales to assets ratio x0.70.60.60.50.5 
Return on assets %11.411.25.54.75.1 
Return on equity %15.113.91.10.41.8 
Return on capital %17.216.47.06.66.3 
Exports to sales %00000 
Imports to sales %14.817.017.720.518.4 
Exports (fob) Rs m00000 
Imports (cif) Rs m695921821858736 
Fx inflow Rs m00000 
Fx outflow Rs m0921822858736 
Net fx Rs m0-921-822-858-736 
VENUS REMEDIES CASH FLOW
From Operations Rs m 522 527 678 469 997 
From Investments Rs m -1,039 -947 -672 29 -461 
From Financial Activity Rs m 552 401 -14 -464 -571 
Net Cashflow Rs m 34 -20 -8 35 -35 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 32.9%
Foreign collaborators 0.0%
Indian inst/Mut Fund 0.2%
FIIs 0.6%
ADR/GDR 0.0%
Free float 66.4%
Shareholders 20,121
Pledged promoter(s) holding 36.4%
 

Company Information

REGD OFF SCO 857, 2nd Floor, Cabin No. 10, NAC Manimajra, Chandigarh-160 101
E-MAIL investorgrievance@venusremedies.com WEB www.venusremedies.com
TELEPHONE (0172) 393 3094 FAX (0172) 256 5566
SECTOR PHARMACEUTICALS GROUP MISCELLANEOUS
TR AGENT Link Intime India, A-31, Naraina Indl. Area, Phase 1, New Delhi-28
AUDITOR J. K. Jain & Assoc.
CHM: Pawan Chaudhary (MD) COMP SEC: Neha Kodan YEAR OF INC: 1989 BSE CODE: 526953 FV (Rs): 10 DIV YIELD (%): -

More Pharmaceuticals Company Fact Sheets:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  SUN PHARMA  DIVIS LABORATORIES  ALEMBIC LTD  

Compare VENUS REMEDIES With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  SUN PHARMA  DIVIS LABORATORIES  ALEMBIC LTD  

Compare VENUS REMEDIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 262 Points Up; ONGC & Tata Steel Top Gainers(Closing)

Indian share markets ended the day on a strong note. At the closing bell, the BSE Sensex finished higher by 262 points. While, the NSE Nifty finished up by 91 points.

Views on news

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

My Top Five Stocks After the Karnataka Elections(The 5 Minute Wrapup)

May 16, 2018

The markets seem confused. They're neither going up nor down. What should investors do? Consider Safe Stocks. Here's the top 5 Safe Stocks in the market today.

How A Storm Destroyed Rain Industries... And a Superb Small Cap Stock I Recommend(Profit Hunter)

May 17, 2018

A mutual fund regulation could cause small cap prices to tank - If you haven't been paying attention to your small caps - now is the time to catch the opportunities that start pouring in.

Has the Indian Home Buyer Become Smarter?(Vivek Kaul's Diary)

May 17, 2018

Home loans continue to grow, despite falling sales. What explains this phenomenon?

Beware the 5th year of the Modi Regime(The Honest Truth)

May 22, 2018

2017 was a great year for the market. You were rewarded for taking excessive risk. But Ajit Dayal believes 2018 will be different. You will be rewarded for doing the opposite. Read on to know more...

Beware of Inflated Stock Market Angels(Sector Info)

May 17, 2018

The stock of Vakrangee helps us understand why it's a bad idea to chase high-flying stocks.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES - GLENMARK PHARMA COMPARISON

COMPARE VENUS REMEDIES WITH

MARKET STATS